menu
    • menu
    [{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Acquisition","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Oral Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Oral Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Oral Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"}]

    Find Infections and Infectious Diseases Clinical Drug Pipeline Developments & Deals by Nestle Health Sciences SA

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : $525.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Seres Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health

                            Details : Seres Therapeutics has signed an agreement with Nestlé Health Science to sell its VOWST, an FDA-approved oral therapy for preventing recurrent Clostridioides difficile infections (CDI).

                            Product Name : Vowst

                            Product Type : Probiotic

                            Upfront Cash : $250.0 million

                            June 08, 2024

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : $525.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nestle Health Sciences SA

                            Switzerland arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Nestlé Agrees to Acquire Global Rights to VOWST®, Product it Launched in June 2023

                            Details : Nestlé will acquire certain assets associated with VOWST (fecal microbiota spores), the first and only FDA approved oral therapeutic to prevent recurrence of Clostridioides difficile infection.

                            Product Name : Vowst

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            June 06, 2024

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : $525.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Appro...

                            Details : The agreement aimed to jointly commercialize Vowst (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibiotic treatment for recurrent CDI, follo...

                            Product Name : Vowst

                            Product Type : Probiotic

                            Upfront Cash : $175.0 million

                            May 30, 2023

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : $525.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and...

                            Details : Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).

                            Product Name : Vowst

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seres Therapeutics and Nestlé Health Science Announce FDA Approval of Vowst™ (fecal Microbiota Spores, Live...

                            Details : Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).

                            Product Name : Vowst

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 26, 2023

                            Lead Product(s) : Fecal Microbiota Spores, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Seres Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Galderma

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Galderma

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetaphil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Healing Ointment Usage Post-surgical Procedure

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : Cetaphil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firmicute Species Bacterial Spore

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Seres Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium

                            Details : SER-109 administration resulted in the rapid engraftment of SER-109-derived bacterial species into the gastrointestinal tract as soon as one week following dosing. This engraftment was maintained at subsequent timepoints.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            January 19, 2021

                            Lead Product(s) : Firmicute Species Bacterial Spore

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Seres Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firmicute Species Bacterial Spore

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Seres Therapeutics

                            Deal Size : $525.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

                            Details : Companies Agree to Jointly market SER-109 microbiome therapeutic to treat recurrent C. difficile Infection. SER-109 is comprised of purified Firmicutes spores, based on their modulatory role in the life cycle of C. difficile and disease pathogenesis.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : $175.0 million

                            January 07, 2021

                            Lead Product(s) : Firmicute Species Bacterial Spore

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Seres Therapeutics

                            Deal Size : $525.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fiber

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of a Specific Blend of Fibers and Probiotics on the Microbiome

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            June 09, 2020

                            Lead Product(s) : Fiber

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Promitor

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fiber Tolerability in Children Aged 3-7 Year

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 09, 2016

                            Lead Product(s) : Promitor

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth